134 related articles for article (PubMed ID: 36849332)
41. Frequent microbiological surveillance during inpatient cystic fibrosis pulmonary exacerbations has limited clinical value.
Song WH; Wong KS; Goldfarb DM; Bone JN; Rayment JH
J Cyst Fibros; 2024 Mar; 23(2):282-287. PubMed ID: 37838488
[TBL] [Abstract][Full Text] [Related]
42. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
[TBL] [Abstract][Full Text] [Related]
43. Measuring the impact of an empiric antibiotic algorithm for pulmonary exacerbation in children and young adults with cystic fibrosis.
Kennedy C; Greenberg I; Perez GF; Chaney H; Sami I; Ogunlesi F; Koumbourlis AC; Hammer B; Hamdy RF; Cogen JD; Payne AS; Hahn A
Pediatr Pulmonol; 2022 Apr; 57(4):965-975. PubMed ID: 35084122
[TBL] [Abstract][Full Text] [Related]
44. Application of multiple event analysis as an alternative approach to studying pulmonary exacerbations as an outcome measure.
Juarez-Colunga E; Rosenfeld M; Zemanick ET; Wagner B
J Cyst Fibros; 2020 Jan; 19(1):114-118. PubMed ID: 30642785
[TBL] [Abstract][Full Text] [Related]
45. A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care.
Sawicki GS; Ayyagari R; Zhang J; Signorovitch JE; Fan L; Swallow E; Latremouille-Viau D; Wu EQ; Shi L
Pediatr Pulmonol; 2013 Oct; 48(10):954-61. PubMed ID: 23255309
[TBL] [Abstract][Full Text] [Related]
46. Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis.
VanDevanter DR; Heltshe SL; Hilliard JB; Konstan MW
J Cyst Fibros; 2021 Mar; 20(2):257-263. PubMed ID: 32505525
[TBL] [Abstract][Full Text] [Related]
47. AtbFinder Diagnostic Test System Improves Optimal Selection of Antibiotic Therapy in Persons with Cystic Fibrosis.
Tetz G; Kardava K; Vecherkovskaya M; Hahn A; Tsifansky M; Koumbourlis A; Tetz V
J Clin Microbiol; 2023 Jan; 61(1):e0155822. PubMed ID: 36602344
[TBL] [Abstract][Full Text] [Related]
48. A Pilot Randomized Clinical Trial of Pediatric Cystic Fibrosis Pulmonary Exacerbations Treatment Strategies.
Sanders DB; Bartz TM; Zemanick ET; Hoppe JE; Hinckley Stukovsky KD; Cogen JD; Bendy L; McNamara S; Enright E; Kime NA; Kronmal RA; Edwards TC; Morgan WJ; Rosenfeld M
Ann Am Thorac Soc; 2023 Dec; 20(12):1769-1776. PubMed ID: 37683122
[No Abstract] [Full Text] [Related]
49. Clinical implications and characterization of Group A Streptoccoccus infections in adults with cystic fibrosis.
Skolnik K; Nguyen A; Somayaji R; Thornton CS; Waddell B; Surette MG; Rabin HR; Parkins MD
BMC Pulm Med; 2015 Dec; 15():161. PubMed ID: 26651825
[TBL] [Abstract][Full Text] [Related]
50. Re-examining baseline lung function recovery following IV-treated pulmonary exacerbations.
Heltshe SL; Russell R; VanDevanter DR; Sanders DB
J Cyst Fibros; 2023 Sep; 22(5):864-867. PubMed ID: 36803635
[TBL] [Abstract][Full Text] [Related]
51. The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis.
VanDevanter EJ; Heltshe SL; Skalland M; Lechtzin N; Nichols D; Goss CH
J Cyst Fibros; 2021 Nov; 20(6):932-936. PubMed ID: 33685776
[TBL] [Abstract][Full Text] [Related]
52. Duration of intravenous antibiotic therapy in people with cystic fibrosis.
Abbott L; Plummer A; Hoo ZH; Wildman M
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD006682. PubMed ID: 31487382
[TBL] [Abstract][Full Text] [Related]
53. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2015 Nov; (11):CD006961. PubMed ID: 26522473
[TBL] [Abstract][Full Text] [Related]
54. Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis.
Wagener JS; VanDevanter DR; Konstan MW; Pasta DJ; Millar SJ; Morgan WJ
Pediatr Pulmonol; 2020 Mar; 55(3):828-834. PubMed ID: 31746561
[TBL] [Abstract][Full Text] [Related]
55. Utilization of antibiotics for methicillin-resistant Staphylococcus aureus infection in cystic fibrosis.
Zobell JT; Epps KL; Young DC; Montague M; Olson J; Ampofo K; Chin MJ; Marshall BC; Dasenbrook E
Pediatr Pulmonol; 2015 Jun; 50(6):552-9. PubMed ID: 25559432
[TBL] [Abstract][Full Text] [Related]
56. Spectrum Of Pulmonary Exacerbation In Children And Adolescent With Cystic Fibrosis And Physicians' Practices: Experience From Tertiary Care Center From Lower-Middle Income Country.
Aziz DA; Shahid S; Alam A; Aziz N; Iftikhar H; Mir F
J Ayub Med Coll Abbottabad; 2021; 33(3):363-367. PubMed ID: 34487639
[TBL] [Abstract][Full Text] [Related]
57. A prospective randomised controlled mixed-methods pilot study of home monitoring in adults with cystic fibrosis.
Nash EF; Choyce J; Carrolan V; Justice E; Shaw KL; Sitch A; Mistry H; Whitehouse JL
Ther Adv Respir Dis; 2022; 16():17534666211070133. PubMed ID: 35274585
[TBL] [Abstract][Full Text] [Related]
58. Measuring recovery in health-related quality of life during and after pulmonary exacerbations in patients with cystic fibrosis.
Flume PA; Suthoff ED; Kosinski M; Marigowda G; Quittner AL
J Cyst Fibros; 2019 Sep; 18(5):737-742. PubMed ID: 30587335
[TBL] [Abstract][Full Text] [Related]
59. Using metabolic potential within the airway microbiome as predictors of clinical state in persons with cystic fibrosis.
Shumyatsky G; Burrell A; Chaney H; Sami I; Koumbourlis AC; Freishtat RJ; Crandall KA; Zemanick ET; Hahn A
Front Med (Lausanne); 2022; 9():1082125. PubMed ID: 36698799
[TBL] [Abstract][Full Text] [Related]
60. Association between serum 25-hydroxyvitamin D level and pulmonary exacerbations in cystic fibrosis.
Vanstone MB; Egan ME; Zhang JH; Carpenter TO
Pediatr Pulmonol; 2015 May; 50(5):441-6. PubMed ID: 25657016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
